Molecular mechanisms of plasmacytoma development and expansion are still unclear, but especially in plasmacytomas of RRMM patients, mutations associated with poor prognosis (TP53, K-RAS, N-RAS, RB1, etc.), were often found. Here, KRAS is linked to plasmacytoma.